Molecular target
PI3K–Akt–mTOR Growth Pathway
Also: mTOR, PI3K/Akt/mTOR · id MTOR
Central regulator of cell growth, metabolism, and proliferation; targeted by mTOR-inhibitor drugs (everolimus, sirolimus, temsirolimus). Polyphenols such as resveratrol, EGCG, and curcumin have been studied for mTOR-pathway modulation in laboratory models.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on PI3K–Akt–mTOR Growth Pathway
These medications have PI3K–Akt–mTOR Growth Pathway among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on PI3K–Akt–mTOR Growth Pathway
Each plant below contains a named compound documented to act on PI3K–Akt–mTOR Growth Pathway. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- CurcuminPolyphenol (curcuminoid)
Beyond its anti-inflammatory NF-kB/COX/LOX activity, curcumin has been investigated in preclinical cancer models for EGFR-pathway and PI3K–Akt–mTOR signaling inhibition and for anti-angiogenic (VEGF) effects. Research only — not a treatment claim.
- Trans-resveratrolStilbenoid polyphenol
Alongside SIRT1/NF-kB activity, resveratrol has been studied for PI3K–Akt–mTOR pathway modulation and anti-angiogenic (VEGF) effects in preclinical models. Research only — not a treatment claim.